Compounds that bind to p185 and methods of using the same

Details Compounds that bind to p185 and methods of using the same Compounds that bind to p185 and methods of using the same

2011-08-16

2011-08-16

Audet, Maury (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S327000, C424S001690

Reexamination Certificate

active

07998924

ABSTRACT:
Novel peptides and pharmaceutical compositions comprising the same are disclosed. Conjugated compositions peptides linked to detectable agents and/or cytotoxic agents are disclosed. Method of detecting tumors that have p185 on tumor cell surfaces are disclosed. Methods of preventing transformation of a normal cell into a tumor cell in an individual at risk of developing a tumor having tumor cells which have p185 on their surfaces are disclosed. Methods of treating an individual who has cancer characterized by tumor cells that have a p185 on their cell surfaces are disclosed.

REFERENCES:
patent: 5637677 (1997-06-01), Greene et al.
patent: 5663144 (1997-09-01), Greene et al.
patent: 5677637 (1997-10-01), Nakazato et al.
patent: 6100377 (2000-08-01), Greene et al.
patent: 6417168 (2002-07-01), Greene et al.
patent: 7179785 (2007-02-01), Greene et al.
patent: 7745577 (2010-06-01), Greene et al.
patent: WO 99/44645 (1999-09-01), None
Berezov et al. J. Med. Chem. Aug. 2, 2001; 44(16); 265-74.
Di Blasio et al., “Noncoded Residues as Building Blocks in the Design of Specific Secondary Structures: Symmetrically Distributed Glycines and β-Alanine”, Biopolymers, Jul. 1993, 33(7), 1037-1049.
Frieden et al., “Adenosine deaminase and adenylate deamnase: comparative kinetic studies with transition state and ground-state analogue inhibitors”, Biochemistry, Nov. 11, 1980, 19(23), 5303-5309.
Hruby, “Conformational and Topographical Consideration in the Design of Biologically Active Peptides”, Biopolymers, Jul. 1993, 33(7), 1073-1082.
Igarashi et al., “Specific binding of a synthetic peptide derived from an antibody complementarity determining region to phosphatidylserine”, J. Biochem., (Tokyo), Feb. 1995, 117(2), 452-457.
Laune et al., “Systematic Exploration of the Antigen Binding Activity of Synthetic Peptides Isolated from the Variable Regions of Immunoglobulins”, The Journal of Biol. Chemistry, Dec. 5, 1997, 272, 30937-30944.
Leysen et al., “The dissociation rate of unlabeled dopamine antagonists and agonists from the dopamine-D2 receptor, application of an original filter method”, J. Recept. Res., (no month available) 1984, 4(7), 817-845.
Lodato et al., “Immunohistochemical Evaluation of c-erbB-2 Oncogene Expression in Ductal Carcinoma In Situ and Atypical Ductal Hyperplasia of the Breast”, Modern Pathology, Jul. 1990, 3(4), 449-454.
Manning et al., “Design of Cyclic and Linear Peptide Antagonists of Vasopressin and Oxytocin: Current Status and Future Directions”, Regulatory Peptides, Apr. 29, 1993, 45(1-2), 279-283.
Markgren et al., “Kinetic analysis of the interaction between HIV-1 protease and inhibitors using optical biosensor technology”, Anal. Biochem., Mar. 1, 2000, 279(1), 71-78.
Matsuyama et al., “A Novel Extracellular Cyclic Lipopeptide which Promotes Flagellum-Dependent and Independent Spreading Growth of Serratia Marcescens”, Journal of Bacteriology, Mar. 1992, 174(6), 1769-1776.
McGrath et al., “Crystal structure of human cathepsin K complexed with a potent inhibitor”, Nat. Struct. Biol., Feb. 1997, 4(2), 105-109.
Meyer et al., “Backward binding and other structural surprises”, Perspect. Drug Discovery Des., Dec. 1995, 3(1), 168-195.
Online-Medical Dictionary, “Amino acid”, http://cancerweb.ncl.ac.uk/cgi-bin/omd?query=amino+acid, Nov. 13, 1997.
Padlan et al., “Structure of an antibody-antigen complex: crystal structure of the HyHEL-10 Fab-lysozyme complex”, Proc. Natl. Acad. Sci. USA, Aug. 1989, 86(15), 5938-5942.
Pargellis et al., “Determination of kinetic rate constants for the binding of inhibitors to HIV-1 protease and for the association and dissociation of active homodimer”, Biochemistry, Oct. 18, 1994, 33(41), 12527-12534.
Park et al., “Rationally Designed anti-HER2
eu peptide mimetic disables P185HER2
eutyrosine kinases in vitro and in vivo”, Nat. Biotechnol., Feb. 2000, 18(2), 194-198.
Ripka et al., “Peptidomimetic Design”, Curr. Opin. Chem. Biol., Aug. 1998, 2(4), 441-452.
Saragovi et al., “Constrained Peptides and Mimetics as Probes of Protein Secondary Structure”, Immunomethods, Aug. 1992, 1(1), 5-9.
Saragovi, et al., “Design and synthesis of mimetic from an antibody complementarity-determining region”, Science Aug. 16, 1991, 253(5021), 792-795.
Sautel et al., “Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor”, Mol. Pharmacol., Aug. 1996, 50(2), 285-292.
Schwartz, “Locating ligand-binding sites in 7TM receptors by protein engineering”, Current Opinion in Biotechnology, Aug. 1994, 5(4), 434-444.
Sheriff et al., “Three-dimensional structure of an antibody-antigen complex”, Proc. Natl. Acad. Sci. USA, Nov. 1987, 84(22), 8075-8079.
Sliwkowski et al., “Nonclinical Studies Addressing the Mechanism of Action of Trastuzumab (Herceptrin)”, Seminars in Oncology, Aug. 26, 1999, 26(4 suppl. 12), 60-70.
Thompson et al., “Design of potent and selective human cathepsin K inhibitors that span the active site”, Proc. Natl. Acad. Sci. USA, Dec. 23, 1997, 94(26), 14249-14254.
Turk et al., “Crystal Structure of Cathepsin B Inhibited with CA030 at 2.0-.ANG. Resolution: A Basis for the Design of Specific Epoxysuccinyl Inhibitors”, Biochemistry, Apr. 1995, 34(14), 4791-4797.
Weiner, “An overview of monoclonal antibody therapy of cancer”, Seminars in Oncology, Aug. 1999, 26(4 suppl. 12), 41-50.
Wood et al., “Novel cyclization chemistry especially suited for biologically derived, unprotected peptides”, Int. J. Peptide Protein-Res., Jun. 1992, 39(6), 533-539.
Yamamoto et al., “Refined X-ray structure of papain. E-64-complex at 2.1-A resolution”, J. Biol. Chem., Aug. 5, 1991, 266(22), 14771-14777.
Yamashita et al., “Structure and design of potent and selective Cathepsin K Inhibitors”, J. Am. Chem. Soc., Nov. 1997, 119(46), 11351-11352.

Affiliated with

Also associated with

Rating

Compounds that bind to p185 and methods of using the same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds that bind to p185 and methods of using the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds that bind to p185 and methods of using the same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2785158